Silexion Seeks 175M Share Authorization and Reverse Split to Avert Nasdaq Delisting
SLXN is trading near its 52-week low of $0.373 (11% above the low).
Summary
Silexion Therapeutics is seeking shareholder approval for a 175 million share authorization increase and a reverse split of up to 1-for-15 to maintain Nasdaq listing compliance. The company's equity has fallen to $44 thousand, far below the $2.5 million minimum, and its stock trades at $0.415.
Key Events · Corporate Governance and Compliance · SLXN
-
Authorized Share Increase Proposal
Proposal to increase authorized ordinary shares by 175,000,000, from 15,900,000 to 190,900,000 — a 1,100% increase. The company states this is the minimum needed to maintain Nasdaq's $2.5 million shareholders' equity requirement.
-
Reverse Share Split Proposal
Proposal to authorize a reverse split at a ratio between 1-for-7 and 1-for-15, with the exact ratio to be determined by the board. The stock currently trades at $0.415, below the $1.00 minimum bid price.
-
Critical Equity Deficiency
Shareholders' equity was $44 thousand as of June 30, 2026, and approximately $3.2 million as of August 13, 2026 after recent transactions. The company must maintain at least $2.5 million to remain listed.
-
Financing and Dilution Risk
The company has $10.9 million remaining under its ATM program and recently completed a $2.5 million public offering in August 2026. The increased authorization could lead to issuance of shares several times the current outstanding count, causing substantial dilution.
Analysis · SLXN · Life Sciences
Silexion is asking shareholders to approve a massive 1,100% increase in authorized shares and a reverse split of up to 1-for-15. The company's equity has fallen to just $44 thousand as of June 30, 2026, far below Nasdaq's $2.5 million minimum, and its stock trades at $0.415 — well under the $1.00 bid requirement. Without these approvals, Silexion faces immediate delisting. The proposals would give the board enormous flexibility to issue shares, potentially diluting existing holders several times over, while the reverse split is designed to mechanically boost the share price. This is a critical survival vote for a company already under going-concern doubt and embroiled in a sponsor lawsuit.
How filings like this one have moved
In the 30 days to Oct 3, 2026, 40.9% of the 313 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.48%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SLXN was trading at $0.42 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $446.7K. The 52-week trading range was $0.37 to $80.00. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.